Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon-beta + human leukocyte interferon-alpha
- Development stage
- Unknown
- Lead developer
- Melinda Magyari
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This drug combination involves the sequential or comparative administration of interferon-beta and natural human leukocyte interferon-alpha (specifically the brand Multiferon). It was investigated in the REPAIR (Response to IFN-alpha in IFN-beta Neutralising Antibody Positive Multiple Sclerosis Patients) Phase 2 clinical trial led by Melinda Magyari at the Danish Multiple Sclerosis Center. The treatment strategy targets patients with relapsing-remitting multiple sclerosis (RRMS) who have developed neutralizing antibodies (NAbs) against interferon-beta, which typically renders that therapy ineffective. Both interferon-alpha and interferon-beta are Type I interferons that signal through the same heterodimeric receptor complex (IFNAR1/IFNAR2). The combination or switch to interferon-alpha is intended to bypass the specific neutralizing antibodies directed at interferon-beta, thereby restoring the induction of interferon-stimulated genes like MX1 and maintaining therapeutic efficacy.
- Brand names
- Multiferon
- Other names
- interferon-betahuman leukocyte interferon-alphanatural human leukocyte interferon-alphaIFN-betaIFN-alpha
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon-beta + human leukocyte interferon-alpha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon-beta + human leukocyte interferon-alpha.